 High-dose cytarabine intensification early therapy childhood acute myeloid leukemia Pediatric Oncology Group study June Pediatric Oncology Group POG pilot study high-dose cytarabine HdA intensification early therapy childhood acute myelogenous leukemia AML group Remission induction therapy courses daunorubicin cytarabine Ara-C thioguanine DAT Postremission therapy sequential courses consisting doses HdA asparaginase L-Asp etoposide VP azacytidine Az prednisone vincristine methotrexate mercaptopurine POMP Ara-C daily days continuous infusion Six doses intrathecal Ara-C CNS prophylaxis December protocol group II doses HdA second DAT induction course postinduction single course HdA/L-Asp courses remainder therapy unchanged forty group patients group II patients assessable groups similar regard clinical prognostic groups significant differences groups regard induction SE group induction deaths deaths remission group Cerebellar toxicity patients group II none group present patients group II event-free survival patients group EFS years SE SE disease-free survival DFS years SE SE differences significant groups children years WBCs outcome EFS SE SE years children equal years WBCs equal EFS SE SE years